BIOHEART-B (02185) surged over 52% in late trading. As of press time, the stock rose 52.15% to HK$9.22, with trading volume reaching HK$98.3 million.

On the news front, on July 15, BIOHEART's Iberis RDN system received official 5-year medical insurance qualification from France (with renewal eligibility), further enhancing the European clinical application support system. Additionally, the company has already obtained clinical application approvals and guideline recommendations in Italy, Germany, and Spain. In July, media reported that the US CMS issued a new proposal recommending RDN inclusion in medical insurance coverage for patients with uncontrolled hypertension.

Notably, in February this year, the Iberis multi-electrode renal artery radiofrequency ablation system (Iberis RDN system) developed by Shanghai Antong Medical, a subsidiary of BIOHEART, completed its first commercial surgery in Germany.

CITIC Securities pointed out that RDN demonstrates significant and long-term effective blood pressure reduction, with simple surgical procedures and low complication rates, indicating broad long-term market potential. BIOHEART's RDN products are currently advancing commercialization both domestically and internationally simultaneously, and analysts recommend monitoring the company's first-year commercialization results in 2025.